Skip to main content
Figure 5 | Breast Cancer Research

Figure 5

From: The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

Figure 5

Distant recurrence-free survival among patients in Stockholm 3 with ER-positive/PgR-positive tumours treated with tamoxifen in relation to p4EBP1_S65 and 4EBP1 protein expression. Kaplan–Meier curves and multivariate Cox regression of distant recurrence-free survival (DRFS) among patients in the Stockholm 3 cohort with ER-positive/PgR-positive tumours, treated with tamoxifen, in relation to (a) p4EBP1_S65 cytoplasmic protein, (b) p4EBP1_S65 nuclear protein, (c) 4E-binding protein 1 (4EBP1) cytoplasmic protein, (d) 4EBP1 nuclear protein, and (e) 4EBP1protein cytoplasm ≥ nucleus. The Cox analysis included the following variables: tumour size, Nottingham histological grade, and human epidermal growth factor receptor 2 (HER2) status. *For the 4EBP1 analysis, HER2 was divided into four groups due to few events. BCS, breast cancer-specific survival; CI, confidence interval; ER, oestrogen receptor alpha; HR, hazard ratio; PgR, progesterone receptor.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us